<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695446</url>
  </required_header>
  <id_info>
    <org_study_id>BPX-01-C01</org_study_id>
    <nct_id>NCT02695446</nct_id>
  </id_info>
  <brief_title>Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline</brief_title>
  <official_title>Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioPharmX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioPharmX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the skin and plasma concentrations of
      minocycline in subjects undergoing treatment of acne vulgaris with oral extended release
      minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label, non randomized, interventional pilot study evaluating the plasma
      and skin levels of minocycline in 10 subjects with moderate to severe acne vulgaris. Subjects
      with non inflammatory acne of nodular acne will not be enrolled. Subjects will be on an oral
      extended release minocycline regimen of up to 2mg/kg once a day for 4 weeks.

      Steady state levels of minocycline in plasma and skin will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Minocycline Level</measure>
    <time_frame>Assessed at week 2 and week 4; reported at week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin/Dermal Levels of Minocycline</measure>
    <time_frame>Measured at 2 weeks in half the subjects, 4 week biopsies not performed per early stopping rules</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Oral ER Minocycline - Up to 2mg/kg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Oral extended release minocycline</description>
    <arm_group_label>Oral ER Minocycline - Up to 2mg/kg</arm_group_label>
    <other_name>MCN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy male and female subjects 14 to 40 years of age

          -  Moderate to severe inflammatory facial acne vulgaris (EGSA score of 3-5)

          -  Subjects not using oral or topical antibiotic products for at least 30 days prior to
             study entry and willing to refrain from use of oral and topical antibiotics for the
             duration of study participation

          -  Subjects not currently using and willing to refrain from use of other topical acne
             products for the duration of study participation

        Exclusion Criteria:

          -  Mild, non-inflammatory or nodular acne vulgaris

          -  Have current or previous skin cancer

          -  Have a history of skin disease or presence of skin condition the PI believes would
             interfere with the study

          -  Females who report that they are pregnant, planning a pregnancy during the study
             period or breastfeeding

          -  Have conditions or factors that the PI believes may affect the response of the skin or
             the interpretation of the results

          -  Participation in any clinical study within the previous 30 days or plan concurrent
             participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Lessin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGL, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGL Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2017</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral ER Minocycline - Up to 2mg/kg</title>
          <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
Minocycline: Oral extended release minocycline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral ER Minocycline - Up to 2mg/kg</title>
          <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
Minocycline: Oral extended release minocycline</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="14" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Minocycline (ng/ml)</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Minocycline Level</title>
        <time_frame>Assessed at week 2 and week 4; reported at week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral ER Minocycline - Up to 2mg/kg</title>
            <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
Minocycline: Oral extended release minocycline</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Minocycline Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421" spread="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin/Dermal Levels of Minocycline</title>
        <time_frame>Measured at 2 weeks in half the subjects, 4 week biopsies not performed per early stopping rules</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral ER Minocycline - Up to 2mg/kg</title>
            <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
Minocycline: Oral extended release minocycline</description>
          </group>
        </group_list>
        <measure>
          <title>Skin/Dermal Levels of Minocycline</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral ER Minocycline - Up to 2mg/kg</title>
          <description>Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
Minocycline: Oral extended release minocycline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AnnaMarie Daniels</name_or_title>
      <organization>BioPharmX, Inc.</organization>
      <phone>310-701-2080</phone>
      <email>amdaniels@biopharmx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

